A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma, but prevalence increases in late-stage, refractory disease, and the mutations are associated with adverse outcome. This prospective single-arm, open-label, multicenter phase 2 trial assessed the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Giesen, Nicola (VerfasserIn) , Chatterjee, Manik (VerfasserIn) , Scheid, Christof (VerfasserIn) , Poos, Alexandra (VerfasserIn) , Besemer, Britta (VerfasserIn) , Miah, Kaya (VerfasserIn) , Benner, Axel (VerfasserIn) , Becker, Nicole (VerfasserIn) , Moehler, Thomas (VerfasserIn) , Metzler, Ivana (VerfasserIn) , Khandanpour, Cyrus (VerfasserIn) , Seidel-Glätzer, Andrea (VerfasserIn) , Trautmann-Grill, Karolin (VerfasserIn) , Kortüm, K. Martin (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Mechtersheimer, Gunhild (VerfasserIn) , Goeppert, Benjamin (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Weinhold, Niels (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Weisel, Katja (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 6, 2023
In: Blood
Year: 2023, Jahrgang: 141, Heft: 14, Pages: 1685-1690
ISSN:1528-0020
DOI:10.1182/blood.2022017789
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2022017789
Volltext
Verfasserangaben:Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab

MARC

LEADER 00000caa a2200000 c 4500
001 1849779058
003 DE-627
005 20260126180514.0
007 cr uuu---uuuuu
008 230615s2023 xx |||||o 00| ||eng c
024 7 |a 10.1182/blood.2022017789  |2 doi 
035 |a (DE-627)1849779058 
035 |a (DE-599)KXP1849779058 
035 |a (OCoLC)1389528400 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Giesen, Nicola  |d 1983-  |e VerfasserIn  |0 (DE-588)141844272  |0 (DE-627)631828524  |0 (DE-576)32643657X  |4 aut 
245 1 2 |a A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma  |c Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab 
264 1 |c April 6, 2023 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.06.2023 
520 |a Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma, but prevalence increases in late-stage, refractory disease, and the mutations are associated with adverse outcome. This prospective single-arm, open-label, multicenter phase 2 trial assessed the efficacy and safety of combined BRAF/MEK inhibition, using encorafenib and binimetinib, in patients with relapsed/refractory multiple myeloma (RRMM) carrying a BRAFV600E mutation. Patients received 450 mg encorafenib once daily and binimetinib 45 mg twice daily. The primary end point was the overall response rate achieved within the first year after start of treatment according to International Myeloma Working Group criteria. Twelve RRMM patients with a median of 5 prior lines of therapy were enrolled. The overall response rate was 83.3%, with 10 patients achieving at least a partial response. The median progression-free survival was 5.6 months, and overall survival was 55% at 24 months. Emerging resistance to therapy was driven by RAS mutations and structural variants involving the BRAF locus. This is the first prospective clinical trial to demonstrate that combined BRAF/MEK inhibition is highly effective in patients with BRAFV600E-mutated RRMM, and it represents a successful targeted precision medicine approach in this disease. This trial was registered at www.clinicaltrials.gov as #NCT02834364. 
700 1 |a Chatterjee, Manik  |e VerfasserIn  |4 aut 
700 1 |a Scheid, Christof  |e VerfasserIn  |4 aut 
700 1 |a Poos, Alexandra  |d 1988-  |e VerfasserIn  |0 (DE-588)1178400417  |0 (DE-627)1049344812  |0 (DE-576)517770393  |4 aut 
700 1 |a Besemer, Britta  |e VerfasserIn  |4 aut 
700 1 |a Miah, Kaya  |e VerfasserIn  |0 (DE-588)1387997181  |0 (DE-627)195024055X  |4 aut 
700 1 |a Benner, Axel  |d 1959-  |e VerfasserIn  |0 (DE-588)106584686X  |0 (DE-627)81687221X  |0 (DE-576)425536602  |4 aut 
700 1 |a Becker, Nicole  |e VerfasserIn  |0 (DE-588)1292800682  |0 (DE-627)1849783829  |4 aut 
700 1 |a Moehler, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Metzler, Ivana  |e VerfasserIn  |4 aut 
700 1 |a Khandanpour, Cyrus  |d 1977-  |e VerfasserIn  |0 (DE-588)130838004  |0 (DE-627)506356671  |0 (DE-576)298368315  |4 aut 
700 1 |a Seidel-Glätzer, Andrea  |e VerfasserIn  |0 (DE-588)1190052709  |0 (DE-627)1668735849  |4 aut 
700 1 |a Trautmann-Grill, Karolin  |e VerfasserIn  |4 aut 
700 1 |a Kortüm, K. Martin  |e VerfasserIn  |4 aut 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
700 1 |a Mechtersheimer, Gunhild  |e VerfasserIn  |0 (DE-588)1021953024  |0 (DE-627)715842595  |0 (DE-576)170441598  |4 aut 
700 1 |a Goeppert, Benjamin  |d 1977-  |e VerfasserIn  |0 (DE-588)1022581635  |0 (DE-627)717004244  |0 (DE-576)365641324  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Weinhold, Niels  |e VerfasserIn  |0 (DE-588)141225688  |0 (DE-627)626149576  |0 (DE-576)322607388  |4 aut 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Weisel, Katja  |e VerfasserIn  |4 aut 
700 1 |a Raab, Marc-Steffen  |d 1973-  |e VerfasserIn  |0 (DE-588)124052460  |0 (DE-627)706520998  |0 (DE-576)293998027  |4 aut 
773 0 8 |i Enthalten in  |t Blood  |d Washington, DC : American Society of Hematology, 1946  |g 141(2023), 14 vom: Apr., Seite 1685-1690  |h Online-Ressource  |w (DE-627)266886647  |w (DE-600)1468538-3  |w (DE-576)075961938  |x 1528-0020  |7 nnas  |a A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma 
773 1 8 |g volume:141  |g year:2023  |g number:14  |g month:04  |g pages:1685-1690  |g extent:6  |a A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma 
856 4 0 |u https://doi.org/10.1182/blood.2022017789  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
951 |a AR 
992 |a 20230615 
993 |a Article 
994 |a 2023 
998 |g 1387997181  |a Miah, Kaya  |m 1387997181:Miah, Kaya  |d 50000  |e 50000PM1387997181  |k 0/50000/  |p 6 
998 |g 124052460  |a Raab, Marc-Steffen  |m 124052460:Raab, Marc-Steffen  |d 910000  |d 910100  |e 910000PR124052460  |e 910100PR124052460  |k 0/910000/  |k 1/910000/910100/  |p 22  |y j 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 20 
998 |g 141225688  |a Weinhold, Niels  |m 141225688:Weinhold, Niels  |d 910000  |d 910100  |e 910000PW141225688  |e 910100PW141225688  |k 0/910000/  |k 1/910000/910100/  |p 19 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 18 
998 |g 1022581635  |a Goeppert, Benjamin  |m 1022581635:Goeppert, Benjamin  |d 50000  |e 50000PG1022581635  |k 0/50000/  |p 17 
998 |g 1021953024  |a Mechtersheimer, Gunhild  |m 1021953024:Mechtersheimer, Gunhild  |d 910000  |d 912000  |d 50000  |e 910000PM1021953024  |e 912000PM1021953024  |e 50000PM1021953024  |k 0/910000/  |k 1/910000/912000/  |k 0/50000/  |p 16 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 15 
998 |g 1190052709  |a Seidel-Glätzer, Andrea  |m 1190052709:Seidel-Glätzer, Andrea  |d 910000  |d 913000  |e 910000PS1190052709  |e 913000PS1190052709  |k 0/910000/  |k 1/910000/913000/  |p 12 
998 |g 1292800682  |a Becker, Nicole  |m 1292800682:Becker, Nicole  |d 910000  |d 910100  |e 910000PB1292800682  |e 910100PB1292800682  |k 0/910000/  |k 1/910000/910100/  |p 8 
998 |g 106584686X  |a Benner, Axel  |m 106584686X:Benner, Axel  |d 50000  |e 50000PB106584686X  |k 0/50000/  |p 7 
998 |g 1178400417  |a Poos, Alexandra  |m 1178400417:Poos, Alexandra  |d 910000  |d 910100  |e 910000PP1178400417  |e 910100PP1178400417  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 141844272  |a Giesen, Nicola  |m 141844272:Giesen, Nicola  |p 1  |x j 
999 |a KXP-PPN1849779058  |e 4338693878 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1849779058","physDesc":[{"extent":"6 S."}],"title":[{"title":"A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma","title_sort":"phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 15.06.2023"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"April 6, 2023"}],"relHost":[{"recId":"266886647","physDesc":[{"extent":"Online-Ressource"}],"disp":"A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaBlood","origin":[{"dateIssuedKey":"1946","dateIssuedDisp":"1946-","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","publisher":"American Society of Hematology ; Saunders ; HighWire Press"}],"title":[{"title":"Blood","title_sort":"Blood","subtitle":"journal of the American Society of Hematology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 21.04.2023"],"pubHistory":["1.1946 -"],"titleAlt":[{"title":"Blood online"}],"corporate":[{"display":"American Society of Hematology","role":"isb"}],"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"part":{"volume":"141","year":"2023","issue":"14","text":"141(2023), 14 vom: Apr., Seite 1685-1690","extent":"6","pages":"1685-1690"}}],"person":[{"display":"Giesen, Nicola","given":"Nicola","role":"aut","family":"Giesen"},{"display":"Chatterjee, Manik","given":"Manik","role":"aut","family":"Chatterjee"},{"display":"Scheid, Christof","role":"aut","given":"Christof","family":"Scheid"},{"given":"Alexandra","role":"aut","family":"Poos","display":"Poos, Alexandra"},{"family":"Besemer","role":"aut","given":"Britta","display":"Besemer, Britta"},{"family":"Miah","role":"aut","given":"Kaya","display":"Miah, Kaya"},{"role":"aut","given":"Axel","family":"Benner","display":"Benner, Axel"},{"display":"Becker, Nicole","role":"aut","given":"Nicole","family":"Becker"},{"given":"Thomas","role":"aut","family":"Moehler","display":"Moehler, Thomas"},{"family":"Metzler","role":"aut","given":"Ivana","display":"Metzler, Ivana"},{"role":"aut","given":"Cyrus","family":"Khandanpour","display":"Khandanpour, Cyrus"},{"display":"Seidel-Glätzer, Andrea","family":"Seidel-Glätzer","given":"Andrea","role":"aut"},{"family":"Trautmann-Grill","given":"Karolin","role":"aut","display":"Trautmann-Grill, Karolin"},{"display":"Kortüm, K. Martin","role":"aut","given":"K. Martin","family":"Kortüm"},{"role":"aut","given":"Carsten","family":"Müller-Tidow","display":"Müller-Tidow, Carsten"},{"role":"aut","given":"Gunhild","family":"Mechtersheimer","display":"Mechtersheimer, Gunhild"},{"display":"Goeppert, Benjamin","family":"Goeppert","given":"Benjamin","role":"aut"},{"family":"Stenzinger","role":"aut","given":"Albrecht","display":"Stenzinger, Albrecht"},{"given":"Niels","role":"aut","family":"Weinhold","display":"Weinhold, Niels"},{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"family":"Weisel","role":"aut","given":"Katja","display":"Weisel, Katja"},{"display":"Raab, Marc-Steffen","family":"Raab","given":"Marc-Steffen","role":"aut"}],"id":{"eki":["1849779058"],"doi":["10.1182/blood.2022017789"]},"name":{"displayForm":["Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortüm, Carsten Müller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab"]}} 
SRT |a GIESENNICOPHASE2CLIN6202